CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT Number: NCT04687358
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
This study is active but is not currently recruiting participants.
Notify Me7 year and older
All sexes
Observational
Alaska Heart & Vascular Institute, Anchorage, Alaska, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
ACTIVE RP PATIENTS
Select Inclusion Criteria:
Select Exclusion Criteria:
INACTIVE RP PATIENTS
Select Inclusion Criteria:
Select Exclusion Criteria:
Time frame: 5 years
Proportion of patients using 1, 2, 3, or more concomitant RP treatments
Time frame: 5 years
Number of subjects who used each treatment recorded during the study
Time frame: 5 years
Change from baseline through end of observation in corticosteroid use
Time frame: 1 year
Change from baseline in RP disease recurrences within 1 year (from 1 year prior to baseline to 1 year after baseline
Time frame: 5 years
Change from baseline in pericardial rub
Time frame: 5 years
Change from baseline in pericardial effusion
Time frame: 5 years
Change from baseline in fever
Time frame: 5 years
Change from baseline in dyspnea
Time frame: 5 years
Change from baseline in CRP
Time frame: 5 years
Change from baseline in ESR
Time frame: 5 years
Change from baseline in WBC
Time frame: 5 years
Change from baseline in IL-1
Time frame: 5 years
Change from baseline in IL-6
Time frame: 5 years
Change from baseline in ST-, PR-, QRS- and QT- intervals
Time frame: 5 years
Change from baseline in echocardiogram
Time frame: 5 years
Change from baseline in chest x-ray
Time frame: 5 years
Change from baseline in cMRI
Time frame: 5 years
Change from baseline in CMR
Time frame: 5 years
Change from baseline in MDCT
Time frame: 5 years
Rate of adverse events reported by PC treatment
Time frame: 5 years
Change from baseline in PROMIS-29
Time frame: 5 years
Change from baseline in PROMIS Pediatric/Parent 25
Time frame: 5 years
Change from baseline in ISI
Time frame: 5 years
Change from baseline in PGIPS
Time frame: 5 years
Change from baseline in PPNRS
Time frame: 5 years
Change from baseline in D12 outcome measures
Kiniksa Pharmaceuticals International, plc
Industry
Acronym: RESONANCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06708299
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07288216
Cardiovascular Diseases, Disease Attributes
Phoenix, Arizona, United States
View Trial DetailsNCT07010159
Cardiovascular Diseases, Disease Attributes
Gilbert, Arizona, United States
View Trial DetailsNCT06836232
Cardiovascular Diseases, Heart Diseases
Tucson, Arizona, United States
View Trial Details